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Background: This study explored the pharmacokinetic parameters and tissue distribution of 
magnetic iron oxide nanoparticles (Fe3O4 MNPs) in imprinting control region (ICR) mice.
Methods: The Fe3O4 MNPs were synthesized by chemical coprecipitation, and their morphology 
and appearance were observed by transmission electron microscopy. ICR mice were divided 
into a control group and a Fe3O4 MNP-treated group. Probable target organs in ICR mice were 
observed, and the pharmacokinetic parameters and biodistribution of Fe3O4 MNPs in tissues 
were identified using atomic absorption spectrophotometry.
Results: Fe3O4 MNPs were spherical with a well distributed particle diameter, and were 
  distributed widely in various target organs and tissues including the heart, liver, spleen, lungs, 
kidneys, brain, stomach, small intestine, and bone marrow. The majority of Fe3O4 MNPs were 
distributed to the liver and the spleen. Fe3O4 MNP levels in brain tissue were higher in the Fe3O4 
MNP-treated group than in the control group, indicating that Fe3O4 MNPs can penetrate the 
blood–brain barrier.
Conclusion: These results suggest that the distribution of Fe3O4 MNPs was mostly in the 
liver and spleen, so the curative effect of these compounds could be more pronounced for liver 
tumors. Furthermore, Fe3O4 MNPs might be used as drug carriers to overcome   physiologic 
barriers.
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Introduction
With the development of nanotechnology, magnetic nanoparticles have shown 
  application prospects since the 1970s.1 Much attention has been paid over the past 
few years to the study of magnetic nanoparticles due to their particularly large 
  surface-  to-volume ratio, quantum size effect, and magnetic character, as well 
as their potential application in the areas of bioscience and medicine. Recently, 
magnetic nanoparticles have been used more and more frequently in biomedical and 
biotechnology studies, including targeted drug delivery, tumor magnetic hyperthermia 
therapy, contrast enhancement of magnetic resonance imaging, biosensors, rapid 
separation in environmental biology, and concentration tracing of specific targets, such 
as bacteria, leukocytes, and proteins.2 So far, the magnetic nanoparticles with clinical 
applications are mainly composed of magnetic iron oxide, which has good chemical 
stability, magnetic responsiveness, and biocompatibility, in addition to possessing 
the general characteristics of nanoparticles. Moreover, iron oxide nanoparticles are 
the only magnetic nanomaterials approved for clinical use by the US Food and Drug 
Administration (FDA),3,4 and the preparation method is relatively simple.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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In our previous studies,5,6 we have demonstrated that 
Fe3O4 MNPs combined with chemotherapeutic drugs can 
inhibit tumor proliferation and induce apoptosis of tumor 
cells in a dose- and time-dependent manner, which may 
be related to changes in drug formulation caused by the 
magnetic nanomaterials. However, the in vivo metabolic 
processes of Fe3O4 MNPs within the organism, as well as 
their distribution in the important organ tissues, are as yet 
not completely understood.7 Using chemical coprecipitation 
to synthesis Fe3O4 MNPs, we selected imprinting control 
region (ICR) mice as an investigative model. The mice were 
given the Fe3O4 NMPs by the intragastric route in view of 
the application perspective of Fe3O4 NMPs, and the concen-
trations of Fe3O4 MNPs in different organs and tissues were 
measured at particular time points using atomic absorption 
spectrophotometry. The pharmacokinetic parameters and 
biodistribution of Fe3O4 MNPs in tissues and the probable 
target organs in mice were determined to provide theoretic 
evidence for follow-up research and clinical application.
Materials and methods
Animals
ICR mice (6–8 weeks of age) weighing 18–22 g were used for 
the pharmacokinetic and tissue distribution studies, and were 
purchased from the Experimental Animal Center at Nantong 
University (Animal Certificate of Conformity SCXK 2008-
0010). All animal experiments were evaluated and approved 
by the Animal and Ethics Review Committee of the South-
east University. The mice were kept at a room temperature 
controlled at 22° with relative humidity   controlled at about 
45% ± 5%, fed with standard solid composite feedstuff, and 
received tap water ad libitum as previously described.8
Main apparatus and reagents
The main apparatus and reagents used in this experiment 
were an atomic absorption spectrophotometer (HG-9602A, 
Shenyang Huaguang Precise Instrument Co., Ltd), a 
transmission electron microscope (TEM; Sujing Group 
Antai Co., Ltd), and an iron normostock solution (500 mg/L, 
Institute for Reference Materials of SEPA).
Preparation of Fe3O4 NMPs
As described previously,9 we dissolved a quantity of ferric 
chloride hexahydrate (0.02 mol/L) and ferrous sulfate 
  heptahydrate (0.012 mol/L) in 200 mL of deionized water 
under nitrogen protection. Ammonium hydroxide 25% 
was then added slowly with vigorous magnetic force 
stirring until pH was 9. The procedure took 30 minutes to 
generate a dark precipitate. Next, we separated the resultant 
with a permanent magnet and washed this repeatedly with 
deionized water 5–7 times until the pH of the supernatant 
was 7. Finally, the resultant was lyophilized and observed 
under TEM.
experimental group
Forty-two ICR mice were divided into two groups. 
Thirty-six mice were divided (n = 6) into A, B, C, D, E, and 
F experimental groups, given 600 mg/kg Fe3O4 MNPs by 
intragastric administration, and fed a normal diet. Another six 
control mice were given 0.5 mL of sterile physiologic saline 
by intragastric administration and also fed a normal diet.
Preparation of sample
After intragastric administration, 0.2–0.5 mL of blood from 
one mouse in each group were collected into an ethylene-
diaminetetraacetic acid tube by enucleating eyeballs at the 
time points of zero minutes, hours 1, 3, 5, 6, and 7, and days 
1, 3, 5, 7, and 10. The mice were then sacrificed by cervi-
cal dislocation, and samples of heart, liver, spleen, lungs, 
kidneys, bone marrow, brain, stomach, and small intestine 
were collected. After removing the fatty and connective 
tissue on the joint, the remaining tissues were washed with 
physiologic saline, dried with filter paper, and weighed to 
determine Fe3O4 MNP content.
Distribution and concentration  
of Fe3O4 NMPs
Tissue samples of heart, liver, spleen, lungs, kidney, brain, 
stomach, and small intestine were freeze-dried and digested 
using microwave digestion with a HNO3-HClO4(V:V = 5:1) 
acid mixture. Each digested sample (0.2 g) was diluted to 
50 mL with deionized water, while the heparinized blood was 
diluted in 0.02% Triton X-100 and 0.02% HNO3. The iron 
elements of the spectrum were absorbed by iron atoms of the 
sample steam, and iron content in the sample was determined 
using atomic absorption spectrophotometry.
Results
Morphology and appearances
The size and appearance of the Fe3O4 MNPs were examined 
by TEM. Figure 1 shows representative images of the spinel 
ferrite compounds, which were spherical with a narrow 
diameter distribution, and the average particle size observed 
under TEM was 20 nm after being lyophilized (Figure 1).International Journal of Nanomedicine 2010:5
Figure 1 Image of magnetic nanoparticles of Fe3O4 under transmission electron 
microscope. Bar = 20 nm (40,000×).
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Figure 2 concentration of Fe3O4 MNPs in peripheral blood of mice (n = 6).
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general condition of mice
Mice in the control group were all in good condition and 
were agile, responsive, and covered with soft and glossy hair. 
Their consumption of water and food was normal, and their 
stool was formed and yellowish-brown. Those treated with 
Fe3O4 MNPs showed less activity and gathered together with 
enhanced resistance, and had slightly disordered hair. They 
ate and drank a little less, but all survived for the duration 
of monitoring.
Blood concentration of Fe3O4  
MNPs at different time points
The results of atomic absorption spectrophotometry 
showed that the highest concentration of Fe3O4 MNPs 
in the peripheral blood of mice was 439 ± 28 µg/mL at 
six hours in the experimental group after intragastric dos-
ing, and decreased slowly but remained at a higher level 
until it reached another distribution peak of 436 ± 32 µg/mL 
on day 5 and then gradually declined again. During the 
entire observation period, the concentration of Fe3O4 
MNPs in the experimental group at particular time points 
was higher than that of the control group, and there were 
significant differences between the groups (P , 0.05, 
Figure 2).
Distribution of Fe3O4 MNPs in various 
organs and tissues
The distribution of Fe3O4 MNPs in the various organs and 
tissues is shown in Figures 3 and 4. By comparing the 
concentrations of Fe3O4 MNPs at all time points between 
the experimental and control groups, there were statistically 
significant differences in heart and bone marrow tissue 
distribution (P , 0.05) in the liver and small intestine on 
days 1, 3, and 7; in the spleen and brain on days 1 and 3; 
in the lungs at six hours; in the kidneys at six hours and 
on day 1; and in the stomach from six hours to day 7 after 
administration, suggesting that Fe3O4 MNPs are distributed 
widely in various organs in vivo, including the heart, liver, 
spleen, lungs, kidneys, bone marrow, brain, stomach, and 
small intestine. Furthermore, we also found that the peak 
distribution of Fe3O4 MNPs in various organs and tissues 
was different. There were two distribution peaks in the liver. 
The first distribution peak was on day 1 and then decreased 
gradually until it reached a second peak on day 7 after admin-
istration. The second peak concentration of Fe3O4 MNPs was 
208 ± 16 µg/g and was slightly lower compared with day 1, 
but there was no significant difference between the two peak 
values (P . 0.05). While the concentration of Fe3O4 MNPs 
in the heart or spleen increased gradually with the passage of International Journal of Nanomedicine 2010:5
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Figure 3 The concentrations of Fe3O4 MNPs in tissues of mice (n = 6). A heart, B liver, C spleen, D lungs, E kidneys, F brain, G stomach, and H small intestine.
Table 1 concentration of magnetic Fe3O4 nanoparticles in bone 
marrow of mice (n = 6 ± standard deviation)
Times concentration (μg/mL)  
0 minute  0.49 ± 0.08
6 hours  1.03 ± 0.13
  1 day  1.97 ± 0.12
  3 days  1.96 ± 0.10
  5 days  1.40 ± 0.24
  7 days  1.00 ± 0.14
  10 days  0.81 ± 0.16
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time, the peak values were 119 ± 9 µg/g and 211 ± 18 µg/g, 
respectively, on day 3 after dosing. The value in the lung was 
131 ± 15 µg/g at six hours after dosing, and then decreased 
steadily. Levels in both kidneys also peaked six hours after 
dosing, and decreased gradually to a small degree. Brain 
levels rose rapidly after dosing, achieved a peak value of 
58 ± 16 µg/g on day 3, and thereafter decreased gradually. 
Meanwhile, peak stomach, small intestine, and bone marrow 
levels were reached on day 1, with respective peak values of 
106 ± 10 µg/g, 79 ± 11 µg/g, and 1.97 ± 0.12 µg/g. Interest-
ingly, concentrations of Fe3O4 MNPs were higher in the liver 
and spleen than those in other organs. Maximum uptake in 
the liver was 237 ± 29 µg/g, reached on day 1, and that in 
the spleen was 211 ± 18 µg/g, reached on day 3 after dosing, 
indicating that the liver and spleen were the main distribution 
tissues and are the probable target organs for Fe3O4 MNPs.
Discussion
Iron is an essential element, widely distributed in the body, 
and primarily involved in oxygen transport and utiliza-
tion. Almost all organs contain iron in vivo, but the most 
highly ferruginous organs are the liver and spleen, and the 
lungs also contain considerable amounts of iron.10 Iron 
metabolism in the body is a relatively closed system11,12 
and there is very little loss of body iron in normal circum-
stances compared with metabolism of other materials.13 
Human cells lack an excretion mechanism for iron under 
physiologic conditions and, therefore, iron balance in the 
body is regulated by absorption of dietary iron through the 
small intestine. Fe3O4 MNPs have a diameter of less than 
100 nm. The physical and chemical properties of iron when 
being made into nanoparticles and the iron metabolism 
model in vivo would also be different from that of normal 
ferric iron.
From the results of our experiment, we can see that there 
is a close relationship between the blood concentration-
time changes for Fe3O4 MNPs and changes in their tissue 
concentrations in the liver and spleen. A large number of 
Fe3O4 MNPs were ingested by mononuclear macrophages 
in the liver or spleen after being absorbed into the blood, 
with a distribution peak in blood of 439 ± 28 µg/mL at 
six hours. As a result, the concentration of Fe3O4 MNPs in 
blood declined rapidly, while that in the liver and spleen 
reached highest levels on days 1 and 3, respectively. There-
after, the liver and spleen released ferric iron which partici-
pated in the cycle of iron metabolism in vivo, resulting in 
a decreased concentration of Fe3O4 MNPs in the liver and 
spleen (mainly spleen). An increased concentration of Fe3O4 
MNPs in peripheral blood was observed up to the distribu-
tion peak at day 5 after administration. With the gradual 
senescence of red blood cells and impaired absorption in 
the liver and spleen (mainly the liver), the concentration 
of Fe3O4 MNPs in the liver increased again and reached a 
second distribution peak of 208 ± 16 µg/g on day 7, while International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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that in peripheral blood decreased gradually. Under normal 
circumstances, about 80% of iron is combined with plasma 
transferrin, and enters the bone marrow and participates 
in the synthesis of reticulocytes.15 About four to six days 
later, this iron goes into the circulation again, leading to 
increased iron content in the blood.11 In this experiment, the 
changes in concentration of Fe3O4 MNPs in the peripheral 
blood of mice were consistent with those reported by Moore 
et al.15 The concentration of Fe3O4 MNPs in the kidney 
remained slightly above the background level during the 
entire observation period, indicating that renal excretion 
of iron is modest, which is consistent with a report by 
Pouliquen et al.16
In this study, there was a significant difference in brain tis-
sue concentrations of Fe3O4 MNPs between the experimental 
and control groups, indicating that Fe3O4 MNPs can pen-
etrate the blood–brain barrier. The blood–brain barrier is 
composed of a layer of endothelial capillary cells between 
the blood and the brain, where these cells connect tightly on 
the one hand to prevent invasion by exogenous pathogens 
and, on the other hand, form an obstacle which is hard to 
cross in terms of drug and gene delivery. It is likely that 
utilization of Fe3O4 MNPs as drug carriers may overcome 
the physiologic limitations of drug transport by capillary 
barriers.17 Currently, the mechanism by which nanopar-
ticles traverse the barrier is unclear.18 Although iron oxide 
nanoparticles are known to be well tolerated by the body 
and degrade with time,19 it is worthwhile verifying whether 
the structure of Fe3O4 MNPs changes after digestion and 
absorption through the intestine. Hence, we need to investi-
gate further their potential to cause chronic long-term harm 
in the human body.
Conclusions
This study of the pharmacokinetics and tissue distribution 
of magnetic Fe3O4 nanoparticles in ICR mice showed that 
these nanoparticles were mostly taken up in the liver and 
spleen, so the curative effect could be more pronounced 
for tumors in the liver. Furthermore, Fe3O4 MNPs can 
penetrate the blood–brain barrier, so they might be used 
as drug carriers to overcome the limitations of physiologic 
barriers.
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